Mental Health
News Category
Creative Biolabs Advances Neurodegeneration Research with iPSC Models
Creative Biolabs offers advanced iPSC-derived neuronal models to help researchers overcome limitations of traditional animal models and human tissue s...
HKSTP Leads Largest-Ever Hong Kong Delegation to BIO 2026, Showcasing Life and Health Tech Strength
Hong Kong Science and Technology Parks Corporation (HKSTP) led a record delegation of 41 organizations to BIO 2026 in San Diego, highlighting Hong Kon...
Helus Pharma Surpasses 86% Enrollment in Phase 3 APPROACH Trial for Major Depressive Disorder
Helus Pharma announced that its Phase 3 APPROACH trial evaluating HLP003 for major depressive disorder has surpassed 86% enrollment, keeping the compa...
Onco-Innovations Engages Nanosoft to Advance ONC010 Development
Onco-Innovations has partnered with Nanosoft Polymers to support the manufacturing and formulation development of its lead nanoparticle-based PNKP inh...
Helus Pharma Prices $50 Million Public Offering to Advance Mental Health Programs
Helus Pharma announced the pricing of a $50 million public offering to fund development of its novel serotonergic agonist programs for depression and ...
Onco-Innovations Targets Next-Generation DNA Damage Response Cancer Therapies with ONC010(TM)
Onco-Innovations Limited advances a nanoparticle-encapsulated PNKP inhibitor into a $7 billion DDR market, with preclinical success and strategic part...
Quantum BioPharma's Lucid-MS Targets Myelin Repair in Multiple Sclerosis, Advancing to Phase 2 Trials
Quantum BioPharma's novel drug candidate Lucid-MS, which directly targets myelin sheath repair, is preparing for phase 2 clinical trials, offering a p...
Next-Generation DNA Repair Inhibitors Poised to Capture Billions as Oncology Market Expands
The emerging field of DNA Damage Response inhibitors, beyond established PARP inhibitors, represents a multibillion-dollar opportunity in oncology, wi...
Quantum BioPharma Advances Lucid-MS Toward Phase 2 Trials for Multiple Sclerosis
Quantum BioPharma is advancing Lucid-MS, a first-in-class drug candidate that directly protects the myelin sheath in multiple sclerosis, toward Phase ...
Cancer Nanomedicine Advances as Onco-Innovations Targets Scalability and Regulatory Readiness
Onco-Innovations' ONC010 combines a PNKP inhibitor with a polymer nanodelivery system to improve tumor targeting and tolerability, with recent manufac...
LakeShore Biopharma Completes Going Private Transaction, Ends Public Trading
LakeShore Biopharma has finalized its merger with Oceanpine Skyline Inc., delisting from public markets and becoming a privately held company, signali...
VERAXA Biotech Advances BiTAC-ADC Platform, Reports New Preclinical Data for Selective Cancer Cell Targeting
VERAXA Biotech AG (NASDAQ: VRXA) has released in vitro proof-of-concept data for its BiTAC-ADC platform, demonstrating selective activity against brea...
VERAXA Biotech Reports Positive Preclinical Data for BiTAC-ADC Platform, Seeks Partnerships at BIO 2026
VERAXA Biotech announced new in vitro proof-of-concept data for its BiTAC-ADC platform, showing selective cancer cell destruction, as it prepares to p...
Scientists Identify Enzyme That Could Block Brain Metastases, Potentially Transforming Cancer Treatment
Researchers from King's College London and McMaster University discovered a molecular pathway critical for cancer migration to the brain, which could ...
Lexaria Begins Dosing in Human Study Evaluating Oral Semaglutide Formulations Against Wegovy
Lexaria Bioscience has initiated a 5-week human pilot study testing two oral DehydraTECH-semaglutide compositions against Novo Nordisk's Wegovy tablet...
Quantum BioPharma's Lucid-MS Offers New Hope in Multiple Sclerosis Treatment
Quantum BioPharma Ltd. is featured in a BioMedWire editorial highlighting its novel drug candidate Lucid-MS, which aims to repair myelin damage in mul...
Researchers Warn Against Overuse of Antibiotic Prophylaxis Amid Resistance Concerns
A new publication highlights the risks of antibiotic prophylaxis in driving antimicrobial resistance, urging medical caution and suggesting diagnostic...
Helus Pharma Closes $50 Million Public Offering to Advance Clinical Pipeline
Helus Pharma completed a $50 million public offering, with proceeds allocated to Phase 3 trials for major depressive disorder and other pipeline asset...
Onco-Innovations Featured in BioMedWire Editorial on Emerging DNA Repair Inhibitors
Onco-Innovations Limited is highlighted in a BioMedWire editorial discussing the growing market for next-generation DNA Damage Response inhibitors, wi...